







**3Q 2022 & 9M 2022  
Executive Summary and  
General Comments**

**4 November 2022**

## A Solid Third Quarter That Crossed S\$1 Billion in Revenue

Revenue	Profit Before Tax (PBT)	Net Profit <sup>1</sup>	EPS <sup>2</sup>
S\$1,022.6m  32.8% YoY	S\$118.9m  34.8% YoY	S\$97.4m  26.4% YoY	33.4 cents  26.5% YoY

PBT Margin	Net Profit Margin	NAV/ Share
3Q 2022: 11.6%  3Q 2021: 11.5%	3Q 2022: 9.5%  3Q 2021: 10.0%	S\$9.70 <sup>3</sup>  31 Dec 2021: S\$9.35

1. Net Profit refers to Profit attributable to Owners of the Company
2. Earnings per share (EPS) is on a fully diluted basis
3. As at 30 September 2022

## 3Q 2022 vs 3Q 2021

### Portfolio A

1. Life Science, Genomics, Molecular Diagnostics and Related Materials Technology	Growth
2. Medical Devices and Equipment	Growth
3. Healthcare & Wellness Technology, Lifestyle Consumer Tech, Health Improvement Products and Others	Growth

### Overall Portfolio A Performance

**Growth**



### Portfolio B

4. Instrumentation, Test & Measurement Technology	Growth
5. Networking & Communications, Security & Safety, Building Automation, Industrial IOT	Growth
6. Advanced Payment Systems	Growth
7. Advanced Industrial Technology, Computing & Productivity Systems, Printing & Imaging, Related Components Technology and Others	Growth

### Overall Portfolio B Performance

**Growth**

 Diversified across more than 100 customers





---

# **FINANCIAL PERFORMANCE REVIEW**

(S\$m)	3Q 2022	3Q 2021	YoY (%)
<b>Revenue</b>	1,022.6	769.9	32.8
<b>Profit Before Tax</b>	118.9	88.2	34.8
<b>PBT Margin (%)</b>	11.6	11.5	-
<b>Income tax expense</b>	(21.4)	(11.1)	93.2
<b>Effective Tax Rate (%)</b>	18.0	12.6	-
<b>Net profit</b>	97.4	77.0	26.4
<b>Net Margin (%)</b>	9.5	10.0	-
<b>EPS (cents)</b>	33.4	26.4	26.5

- 3Q 2022 revenue and net profit increased 32.8% and 26.4% YoY respectively.
- 3Q 2022 is the first quarter to cross S\$1 billion mark in revenue since 2017.
- Strong growth was recorded in the instrumentation, test & measurement, life science & genomics and advanced industrials technology domains.

(S\$m)	9M 2022	9M 2021	YoY (%)
<b>Revenue</b>	2,818.7	2,202.1	28.0
<b>Profit Before Tax</b>	331.7	249.9	32.7
PBT Margin (%)	11.8	11.3	-
<b>Income tax expense</b>	(59.7)	(32.4)	84.1
Effective Tax Rate (%)	18.0	13.0	-
<b>Net profit</b>	271.7	217.4	24.9
Net Margin (%)	9.6	9.9	-
<b>EPS (cents)</b>	93.2	74.5	25.1

- 9M 2022 revenue and net profit increased 28.0% and 24.9% YoY respectively.
- Driven by post pandemic demand recovery across all domains, with lifestyle & wellness, life science & genomics and instrumentation, test & measurement technology domains recording strong growth.





---

# **FINANCIAL POSITION AND CASH FLOW**



<b>(S\$m)</b>	<b>30 September 2022</b>	<b>31 December 2021</b>
<b>Cash and Cash Balances</b>	<b>700.7</b>	<b>807.9</b>
<b>Trade Receivables</b>	<b>912.1</b>	<b>829.2</b>
<b>Trade Payables</b>	<b>(638.4)</b>	<b>(643.6)</b>
<b>Inventories</b>	<b>1,253.1</b>	<b>1,049.4</b>
<b>Working Capital</b>	<b>1,526.9</b>	<b>1,235.1</b>
<b>Shareholders' Equity</b>	<b>2,822.7</b>	<b>2,716.4</b>
<b>Total Equity</b>	<b>2,825.8</b>	<b>2,719.5</b>
<b>Net Asset Value per Share (cents)</b>	<b>969.6</b>	<b>934.8</b>

- ▼ The Group continued to maintain a healthy balance sheet with net cash position S\$700.7 million as at 30 September 2022.
- ▼ Inventories remained steady to support customer order fulfillment (30 June 2022: S\$1,250.4 million) in an operating environment where lead times for certain components remain extended.



# OUTLOOK



Venture delivered a solid set of financial results in 3Q 2022. Growth achieved was broad based and diversified across all of Venture's operating technology domains. Year-on-year revenue growth jumped over 32% while the increase in net profit after tax exceeded 26%.

Over the last nine months, strong growth in revenue and profits were recorded across all domains. Venture's Malaysian entities delivered the most impressive contributions to the Group's overall performance.

Beyond FY2022, the science and technology market segments may continue to see volatility if geopolitical tensions, Covid-19 lockdowns and other headwinds remain unabated.

Venture must therefore press on relentlessly to create new differentiating capabilities and strengths to render strong values and beneficial services to all our steadfast customers and business partners globally.

Over the years, Venture has built a robust and healthy balance sheet with zero debt. The Group is resilient and well-positioned with its enhanced differentiating capabilities and strengths to seize strategic business opportunities and scale new heights. Venture will continue to focus and prioritise on building upon our bench strengths of scientific, technology, professional and management leadership, as we move decisively into the future.

This presentation may contain certain forward-looking statements including, but not limited to, statements as to future operating results and plans.

These statements are based on our assumptions and estimates and are subject to known and unknown risks and uncertainties and other factors which may cause the actual results, performance or achievements of the Group to differ materially from any future results, performance or achievements expressed or implied by those projected in the forward-looking statements.

Consequently, readers are cautioned not to place undue reliance on any forward-looking statements.



# Thank You

**For enquiries, please contact:**

**Judy Tan**

**Investor Relations & Corporate Communications**

**+65 6484 8136**

**[judy.tan-th@venture.com.sg](mailto:judy.tan-th@venture.com.sg)**